Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Jacobs

Showing results (651-660 of 802) with videos related to

Pageof 81
Sort By:
Clinical Breast Cancer|February 6, 2010
Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancerSaranya Chumsri, Stacie Jeter, Lisa K Jacobs, et al.
Journal of the American Heart Association|January 1, 2019
Improving Care of STEMI in the United States 2008 to 2012Christopher B Granger, Eric R Bates, James G Jollis, et al.
Circulation|September 20, 2017
Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart AssociationSean van Diepen, Jason N Katz, Nancy M Albert, et al.
Circulation|September 18, 2013
Variable impact of state legislative advocacy on registry participation and regional systems of care implementation: a policy statement from the American Heart AssociationIvan C Rokos, Lee H Schwamm, Madeleine Konig, et al.
Leukemia|September 21, 2018
Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemiaS Degryse, C E de Bock, S Demeyer, et al.
Leukemia|August 31, 2017
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemiaS Degryse, C E de Bock, S Demeyer, et al.
JACC. Cardiovascular Interventions|May 26, 2009
Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trialLauren J Kim, Spencer B King, Kenneth Kent, et al.
Annals of Surgical Oncology|June 7, 2020
Germline Genetic Mutations in a Multi-center Contemporary Cohort of 550 Phyllodes Tumors: An Opportunity for Expanded Multi-gene Panel TestingLaura H Rosenberger, Samantha M Thomas, Suniti N Nimbkar, et al.
Journal of Medicinal Chemistry|May 24, 1996
Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitorsD A Nugiel, K Jacobs, R F Kaltenbach, et al.
Leukemia|December 15, 2019
Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tractGuangzhen Hu, Jessica L Phillips, Surendra Dasari, et al.
Pageof 81

Showing results (651-660 of 802) with videos related to

Sort By:
Pageof 81
Clinical Breast Cancer|February 6, 2010
Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancerSaranya Chumsri, Stacie Jeter, Lisa K Jacobs, et al.
Journal of the American Heart Association|January 1, 2019
Improving Care of STEMI in the United States 2008 to 2012Christopher B Granger, Eric R Bates, James G Jollis, et al.
Circulation|September 20, 2017
Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart AssociationSean van Diepen, Jason N Katz, Nancy M Albert, et al.
Circulation|September 18, 2013
Variable impact of state legislative advocacy on registry participation and regional systems of care implementation: a policy statement from the American Heart AssociationIvan C Rokos, Lee H Schwamm, Madeleine Konig, et al.
Leukemia|September 21, 2018
Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemiaS Degryse, C E de Bock, S Demeyer, et al.
Leukemia|August 31, 2017
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemiaS Degryse, C E de Bock, S Demeyer, et al.
JACC. Cardiovascular Interventions|May 26, 2009
Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trialLauren J Kim, Spencer B King, Kenneth Kent, et al.
Annals of Surgical Oncology|June 7, 2020
Germline Genetic Mutations in a Multi-center Contemporary Cohort of 550 Phyllodes Tumors: An Opportunity for Expanded Multi-gene Panel TestingLaura H Rosenberger, Samantha M Thomas, Suniti N Nimbkar, et al.
Journal of Medicinal Chemistry|May 24, 1996
Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitorsD A Nugiel, K Jacobs, R F Kaltenbach, et al.
Leukemia|December 15, 2019
Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tractGuangzhen Hu, Jessica L Phillips, Surendra Dasari, et al.
Pageof 81